Icatibant Injection and Moexipril
Determining the interaction of Icatibant Injection and Moexipril and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using icatibant together with moexipril. Combining these medications may reduce the effectiveness of both medications. In general, patients with hereditary angioedema should preferably avoid medications like moexipril because they can precipitate or aggravate an attack. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Icatibant and angiotensin-converting enzyme (ACE) inhibitors may antagonize the pharmacological effects of one another. Icatibant is a competitive bradykinin B2 receptor antagonist. In contrast, ACE inhibitors enhance the levels of bradykinin, which is a vasodilator thought to be responsible for the characteristic symptoms of hereditary angioedema including localized swelling, inflammation, and pain. Following bradykinin challenge, intravenous administration of icatibant inhibited the development of bradykinin-induced hypotension, vasodilation, and reflex tachycardia in a dose- and time-dependent manner in healthy young subjects. Icatibant may, therefore, attenuate the antihypertensive effect of ACE inhibitors.
MANAGEMENT: Concomitant use of icatibant and ACE inhibitors should be avoided. Patients with hereditary angioedema (HAE) should generally not take ACE inhibitors because they may precipitate or exacerbate acute attacks of HAE.
- "Product Information. Firazyr (icatibant)." Shire US Inc, Florence, KY.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: icatibant
Brand name: Firazyr
Synonyms: Icatibant
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Icatibant Injection-Moexipril and Hydrochlorothiazide
- Icatibant Injection-Moexipril Hydrochloride
- Icatibant Injection-Mogamulizumab
- Icatibant Injection-Mogamulizumab-kpkc
- Icatibant Injection-Mogamulizumab-kpkc Intravenous
- Icatibant Injection-Molindone
- Moexipril-Icatibant Subcutaneous
- Moexipril-ICG for Injection Set
- Moexipril-Iclevia
- Moexipril-Iclusig
- Moexipril-Icosapent
- Moexipril-Icosapent ethyl